Clinically approved to treat chronic hepatitis B (CHB) for approximately 30 years, IFN-α exerts therapeutic effects through its direct anti-HBV activity in hepatocytes and immunomodulatory activity on immune cells [1]. Here, IFNA2 is linked to chronic hepatitis B virus infection.